Insights from ECTRIMS 2025, including anticipated presentations, key takeaways, and how emerging research on DMTs in RRMS may affect patient care.
New clinical trial data show children with MS may benefit as much from treatment with Ocrevus as Gilenya – and for some outcomes, more.
Most relapsing MS patients on Mavenclad did not have confirmed disability progression for at least four years, new Phase 4 ...
Germany is the first European country to launch the product, with further rollouts across Europe to followThe next-generation ...
The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback